PT1194575E - Factor de estimulacao de colonias de granulocitos humanos modificados e processos para a sua producao - Google Patents

Factor de estimulacao de colonias de granulocitos humanos modificados e processos para a sua producao

Info

Publication number
PT1194575E
PT1194575E PT00942494T PT00942494T PT1194575E PT 1194575 E PT1194575 E PT 1194575E PT 00942494 T PT00942494 T PT 00942494T PT 00942494 T PT00942494 T PT 00942494T PT 1194575 E PT1194575 E PT 1194575E
Authority
PT
Portugal
Prior art keywords
csf
modified
processes
human granulocyte
production
Prior art date
Application number
PT00942494T
Other languages
English (en)
Inventor
Gwan Sun Lee
Kwon Se Chang
Jung Sung Youb
Bae Sung Min
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1194575(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PT1194575E publication Critical patent/PT1194575E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT00942494T 1999-07-08 2000-07-07 Factor de estimulacao de colonias de granulocitos humanos modificados e processos para a sua producao PT1194575E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990027418A KR100356140B1 (ko) 1999-07-08 1999-07-08 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법

Publications (1)

Publication Number Publication Date
PT1194575E true PT1194575E (pt) 2005-10-31

Family

ID=36129291

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00942494T PT1194575E (pt) 1999-07-08 2000-07-07 Factor de estimulacao de colonias de granulocitos humanos modificados e processos para a sua producao

Country Status (16)

Country Link
US (2) US20040224393A1 (pt)
EP (1) EP1194575B2 (pt)
JP (1) JP2003504069A (pt)
KR (1) KR100356140B1 (pt)
CN (1) CN1195859C (pt)
AT (1) ATE299187T1 (pt)
AU (1) AU757147C (pt)
BR (2) BR0012265A (pt)
CA (1) CA2378543C (pt)
DE (1) DE60021188T3 (pt)
DK (1) DK1194575T4 (pt)
ES (1) ES2243275T5 (pt)
NZ (1) NZ516476A (pt)
PT (1) PT1194575E (pt)
RU (1) RU2232772C2 (pt)
WO (1) WO2001004329A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
ATE544460T1 (de) 2003-10-24 2012-02-15 Nora Therapeutics Inc Zusammensetzungen und verfahren für eine gesunde schwangerschaft
US8338373B2 (en) 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
BRPI0611221A2 (pt) 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
WO2009139784A1 (en) * 2008-05-13 2009-11-19 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
RU2519031C1 (ru) 2010-01-19 2014-06-10 Ханми Сайенс Ко., Лтд. Жидкие препаративные формы для длительно действующего конъюгата g-csf
RU2612884C2 (ru) * 2010-04-02 2017-03-13 Курна, Инк. Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
KR101831300B1 (ko) 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
RU2467764C2 (ru) * 2011-01-12 2012-11-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Пензенский институт усовершенствования врачей" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных аутоиммунной хронической крапивницей с использованием внутривенного введения препарата "габриглобин"
KR101623906B1 (ko) 2014-07-23 2016-05-24 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
WO2016013725A1 (ko) * 2014-07-23 2016-01-28 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
AU2018215840A1 (en) 2017-02-03 2019-08-01 Hanmi Pharm. Co., Ltd. Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0256843A1 (en) * 1986-08-11 1988-02-24 Cetus Corporation Expression of g-csf and muteins thereof and their use
US5714581A (en) * 1986-12-23 1998-02-03 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JPH02104598A (ja) 1988-04-12 1990-04-17 Kirin Amgen Inc ヒト顆粒球コロニー刺激因子ポリペプチド誘導体
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US6476198B1 (en) * 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
NZ295673A (en) * 1994-11-01 1999-03-29 Wels Wilfried Nucleic acid transfer system using recombinant multi-domain proteins each domain having a different function
US6100070A (en) * 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
KR100316347B1 (ko) * 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
JP4873818B2 (ja) * 2000-05-16 2012-02-08 ボルダー バイオテクノロジー， インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法

Also Published As

Publication number Publication date
BR0012265A (pt) 2002-03-12
AU757147C (en) 2005-03-03
BRPI0012265B1 (pt) 2018-11-21
US7704709B2 (en) 2010-04-27
ES2243275T5 (es) 2009-12-02
AU5710600A (en) 2001-01-30
JP2003504069A (ja) 2003-02-04
WO2001004329A1 (en) 2001-01-18
US20080064066A1 (en) 2008-03-13
US20040224393A1 (en) 2004-11-11
ES2243275T3 (es) 2005-12-01
DK1194575T4 (da) 2009-12-07
CN1195859C (zh) 2005-04-06
KR20010009171A (ko) 2001-02-05
EP1194575A1 (en) 2002-04-10
DE60021188T3 (de) 2010-04-01
KR100356140B1 (ko) 2002-10-19
DE60021188D1 (de) 2005-08-11
EP1194575B2 (en) 2009-08-26
EP1194575A4 (en) 2002-10-24
CA2378543A1 (en) 2001-01-18
DK1194575T3 (da) 2005-10-17
AU757147B2 (en) 2003-02-06
BRPI0012265B8 (pt) 2021-05-25
NZ516476A (en) 2003-09-26
EP1194575B1 (en) 2005-07-06
ATE299187T1 (de) 2005-07-15
CN1360636A (zh) 2002-07-24
DE60021188T2 (de) 2006-04-27
CA2378543C (en) 2010-05-18
RU2232772C2 (ru) 2004-07-20

Similar Documents

Publication Publication Date Title
PT1194575E (pt) Factor de estimulacao de colonias de granulocitos humanos modificados e processos para a sua producao
PL331351A1 (en) Novel strains of escherichia coli, methods of obtaining them and their application in l-treonin production fermentation processes
ATE77104T1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
NZ595500A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
GEP19960519B (en) Method of producing human luecocytary interferons
EP1095158A4 (en) METHOD AND MATERIALS FOR THE PRODUCTION OF GLUCOSAMINE
HUP0203704A2 (hu) L-Pankolakton hidroláz és eljárás D-pantolakton előállítására
DE69739715D1 (de) Herstellungsverfahren von 1,3-propandiol durch rekombinante organismen
ATE513045T1 (de) Stamm von escherichia coli überproduzierend l- threonine, und verfahren zur herstellung von l- threoninen durch fermentation
DK0889949T3 (da) Fermenteringskontrol
DE3683267D1 (de) Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung.
SU1720493A3 (ru) Способ получени штамма SтRертососсUS SaNGUIS, способного секретировать @ -1,3-глюкан-3-глюканогидролазу
HRP960078B1 (en) Dna sequence coding for a protein of a. thaliana having a delta-5, 7 sterol, delta- 7 reductase activity, delta-7-red protein, production process, strains of transformed yeasts, uses
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
DE69736389T8 (de) Proteine mit zellulase-aktivitäten und prozess für ihre herstellung
WO2017181920A1 (zh) 一种重组人粒细胞集落刺激因子的制备方法
EA200100023A1 (ru) Промышленный способ производства гетерологичных белков в пригодных для этого способа штаммах е.coli
DE60328813D1 (de) Mutanten für die herstellung von d-aminosäuren
FR2785291B1 (fr) Procede de production in vivo de proteines chimiquement diversifiees par incorporation d'acides amines non conventionnels
IL158244A0 (en) Plants characterized by enhanced growth and methods and nucleic acid constructs useful for generating same
ATE505550T1 (de) Fermentationsverfahren
HUP9903899A2 (hu) Eljárás L-aminosavak fermentációs előállítására
JPH07203975A (ja) 抗菌活性ペプチドをコードする遺伝子及び抗菌活性ペプチドの製造方法
DK1472347T3 (da) Forbedret proteinekspression i Bacillus Subtilis
CN1030962C (zh) 龋齿预防制剂的制备方法